Meiwei Bio (688062.SH): The clinical trial application for 9MW5211 injection has been approved by the National Medical Products Administration.

Meiwei Biology (688062.SH) announced that the company recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial application of 9MW5211 injection for the treatment of multiple sclerosis (MS) has been approved. In addition, the clinical trial application for the treatment of inflammatory bowel disease (IBD) has been approved by the National Medical Products Administration and the FDA. The company is actively advancing the clinical trial applications for multiple other indications, some of which have been accepted by the National Medical Products Administration. 9MW5211 is a highly specific clearing-type innovative antibody independently developed by the company, targeting the key pathological mechanism mediated by abnormal immune cells in autoimmune diseases with precision intervention. Abnormal activation and tissue infiltration of immune cells are core driving factors in the development of various autoimmune diseases. The molecule targeted by 9MW5211 is specifically expressed on the surface of pathogenic immune cells, serving as an important biological marker for their abnormal activation. By selectively identifying and clearing these pathogenic cells, 9MW5211 can effectively block the immune cascade reaction, thereby alleviating disease progression and improving clinical symptoms.